HEAR Act of 2025
Summary
The HEAR Act of 2025 is an early-stage, unfunded bill with no Senate companion, no committee hearing, and no markup. It proposes Medicare coverage for hearing aids, which would expand the total addressable market for hearing health, but no publicly traded pure-play hearing aid companies are represented in the provided ticker list. The bill has zero legislative momentum and zero appropriated funding, making it a non-event for current market pricing.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.HR6218 has zero legislative momentum: no hearings, no markup, no Senate companion, and no funding mechanism.
- 2.None of the provided tickers are pure-play hearing aid manufacturers; the listed medtech majors have negligible hearing aid exposure.
- 3.The bill's impact on any publicly traded US equity is currently zero — it is a non-event for market pricing.
- 4.Even if passed, implementation would require years of rulemaking and separate appropriation, with no direct revenue impact before 2028 at the earliest.
Market Implications
No market implications. The HEAR Act of 2025 is an early-stage, unfunded, bipartisan-light bill with no action in over five months. None of the provided tickers have a direct causal link to the bill's mechanism. Investors should ignore this bill for portfolio decisions until and unless it receives a committee hearing and a funded legislative vehicle emerges.
Full Analysis
The HEAR Act of 2025 (HR6218) was introduced on November 20, 2025, by Rep. Mullin (D-CA) and referred to two committees: Energy and Commerce, and Ways and Means. As of April 30, 2026 — over five months later — it has received no hearings, no markup, and no companion Senate bill. The bill proposes amending Medicare to cover hearing aids and aural rehabilitation services, which would be a major structural shift: currently, Medicare does not cover hearing aids unless provided as part of a bundled post-surgical benefit (e.g., cochlear implant activation). The Congressional Budget Office would need to score this as a new entitlement with significant costs, yet no funding mechanism is included in the bill text. The bill is an authorization-only measure — it sets policy but does not appropriate any dollars. Without a funding stream (e.g., premium increases, federal budget outlays, or offsetting cuts), it cannot become operational. Six cosponsors, all Democrats or independents, suggests limited bipartisan momentum in a divided 119th Congress with a Republican-controlled House. The provided tickers — Sonos ($SONO), Generac ($GNRC), WesBanco ($WSBC), OraSure ($OSUR), Align ($ALGN), Nova ($NVMI), Zimmer Biomet ($ZBH), Stryker ($SYK), Boston Scientific ($BSX), Medtronic ($MDT) — have no material hearing aid exposure. The major hearing aid pure-plays (Sonova, Demant, WS Audiology, GN Hearing) are not US-listed. The medtech majors listed derive negligible revenue from hearing aids; their hearing businesses, if any, are small divisions of diversified device portfolios. Therefore, no actionable causal chain can be constructed. The competitive landscape for hearing aids in the US is dominated by the 'Big Five' private European manufacturers (Sonova, Demant, WS Audiology, GN Hearing, Starkey) and the recent FDA OTC hearing aid rule (2022) has opened the market to $WSB and $BBWI-adjacent consumer electronics entrants, but none of these are supported by the ticker set. Legislative steps remaining: committee markups in both Energy & Commerce and Ways & Means, House floor vote, Senate introduction and passage (no companion exists), conference, and a funded appropriations vehicle. Given zero movement in five months, this bill is effectively stalled and will not affect 2026 earnings for any listed company.
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
CAPEX & D SQUARE, A JOINT VENTURE LLC: $23.2M Department of Veterans Affairs Contract
Veterans Prosthetics Advancement and Reform Act
NATIONWIDE HEALTHCARE SOLUTIONS, LLC: $16.9M Department of Health and Human Services Contract
Veterans SPORT Act
TRIWEST HEALTHCARE ALLIANCE CORP: $929M Department of Veterans Affairs Contract
TRIWEST HEALTHCARE ALLIANCE CORP: $820M Department of Veterans Affairs Contract
Stop Corporate Inversions Act of 2026
Ensuring Patient Access to Critical Breakthrough Products Act
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Delivering Gold Standard Childhood Vaccine Recommendations for Americans
This executive order directs HHS to establish a 'Gold Standard' childhood vaccine schedule with fewer recommended vaccines than current CDC guidelines, mandates that MMR be administered as three separate single-disease shots when domestically available, and instructs the DOJ to challenge state vaccine mandates that do not provide religious or medical exemptions. It also orders HHS to develop alternative adjuvants to aluminum and improve vaccine safety monitoring, while preserving access to existing vaccines.
Continuing to Protect the Meaning and Value of American Citizenship
This executive order directs federal agencies, including State, Justice, Homeland Security, and Social Security, to deny U.S. citizenship documentation to children born in the U.S. whose parents include alien enemies, foreign government employees, or those involved in commercial birth tourism or surrogacy, or who are born in territories without statutory citizenship. It implements a narrow interpretation of the Fourteenth Amendment following the Supreme Court's decision in Trump v. Barbara, effectively restricting birthright citizenship for specific categories of non-citizen parents.
Ending Birth Tourism
This executive order directs the Secretaries of State and Homeland Security to prevent foreign nationals from entering the U.S. on nonimmigrant visas for the purpose of giving birth (birth tourism), including revoking visas, barring entry, and taking action against facilitators. It defines birth tourism as entry via nonimmigrant visa for childbirth and allows humanitarian or national interest exemptions.
Free — no credit card
Get the next market-moving signal before the news does
HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →